林晨 刘湘鄂 　吴天玉

【摘要】 目的：研究康艾注射液輔助化疗联合内分泌治疗中晚期前列腺癌的效果，指导临床用药。方法：选取2013年1月-2017年1月于笔者所在医院住院治疗的90例中晚期前列腺癌患者，随机分为观察组与对照组，每组45例，两组患者均行睾丸去势术，术后对照组口服氟他胺片，观察组在对照组基础上采用多西他赛化疗，康艾注射液辅助治疗，治疗6个月后对比两组患者近期疗效、前列腺体积、血清前列腺特异抗原（PSA）、最大尿流率（MFR）、残余尿量、国际前列腺症状评分（IPSS）、肿瘤患者生活质量评分（QOL）及健康调查简表（MOS SF-36）评分。结果：治疗6个月后，观察组近期总有效率高于对照组，差异有统计学意义（P<0.05），两组肿瘤控制率比较差异无统计学意义（P>0.05）;观察组前列腺体积、血清PSA水平、残余尿量均低于对照组，MFR高于对照组，差异均有统计学意义（P<0.05）;观察组IPSS评分低于对照组，QOL、MOS SF-36评分均高于对照组，差异均有统计学意义（P<0.05）。结论：采用康艾注射液辅助化疗联合内分泌治疗中晚期前列腺癌可显著提高效果，改善患者生活质量，值得临床推广运用。

【关键词】 康艾注射液 多西他赛 内分泌治疗 中晚期前列腺癌

doi：10.14033/j.cnki.cfmr.2019.28.003 文献标识码 A 文章编号 1674-6805（2019）28-000-03

Therapeutic Effect of Kangai Injection Adjuvant Chemotherapy Combined with Endocrine Therapy on Advanced Prostate Cancer/LIN Chen， LIU Xiange， WU Tianyu. //Chinese and Foreign Medical Research， 2019， 17（28）： -9

[Abstract] Objective： To study and evaluate the efficacy of Kangai Injection adjuvant chemotherapy combined with endocrine therapy for advanced prostate cancer and to guide clinical drug use. Method： Ninety patients with advanced prostate cancer who were hospitalized in our hospital from January 2013 to January 2017 were randomly divided into the observation group and the control group， with 45 cases in each group. Both groups underwent testicular castration. The control group received oral Flutamide Tablets. The observation group was treated with Docetaxel chemotherapy and Kangai Injection on the basis of the control group. After 6 months of treatment， the short-term efficacy， prostate volume and serum prostate specific antigen （PSA）， maximum urinary flow rate （MFR）， residual urine volume， international prostate symptom score （IPSS）， quality of life （QOL）， and health survey profile （MOS SF-36） scores of the two groups were compared. Result： After 6 months of treatment， the total effective rate of the observation group was higher than that of the control group， the difference was statistically significant （P<0.05）. There was no significant difference in tumor control rate （P>0.05）. The prostate volume， serum PSA level and residual urine volume in the observation group were lower than those in the control group， and the MFR was higher than that of the control group， the differences were statistically significant （P<0.05）. The IPSS score was lower than that of the control group， and the QOL and MOS SF-36 scores were higher than those of the control group， the differences were statistically significant （P<0.05）. Conclusion： Kangai Injection adjuvant chemotherapy combined with endocrine therapy for advanced prostate cancer can significantly improve the efficacy and improve the quality of life of patients， which is worthy of clinical application.

[Key words] Kangai Injection Docetaxel Endocrine therapy Advanced prostate cancer

First-authors address： The Third Peoples Hospital of Jingzhou， Jingzhou 434000， China

前列腺癌是发于男性的一种常见恶性肿瘤，近年来，亚洲前列腺癌发病率及病死率均显著上升[1]，中国前列腺癌发病率也有逐年上升的趋势。早期前列腺癌的治疗以手术治疗为主，预后较好，但由于其病程较长，早期各种临床表现与良性前列腺增生类似，不易诊断，多数患者确诊时已为中晚期，合并下尿路梗阻的症状，且一般患者年龄较大，不适宜根治性前列腺切除术，一线治疗方案为姑息性内分泌治疗，但单纯的内分泌疗法无法有效抑制患者肿瘤生长[2]，联合化疗可有效杀伤肿瘤细胞，但由于化疗药物副作用明显，采用益气扶正中药辅助治疗可增效减毒。……